Bioprocess Filtration | Market Size, Share & Growth Report 2024-2030
The Bioprocess Filtration Market Report is Segmented by Product Type (Membrane Filters, Depth Filters, Cartridge Filters, Capsule Filters, and Filter Presses), Application (Bioprocesses, Pharmaceutical, Food and Beverage, Water and Wastewater Treatment, and Others), Distribution Channel (Direct Sales and Distributor Sales), Material (Polyethersulfone, Nylon, Cellulose Acetate, Polypropylene, and Others).
Bioprocess Filtration Market
Market Analysis
How the market stands today, and what is shaping it
The global bioprocess filtration market was estimated at approximately USD 5.43 billion in 2024 and is projected to reach around USD 15.45 billion by 2030, representing a CAGR of approximately 19.04% during 2024–2030, based on Core Market Research estimates. The market supplies membrane and depth filtration in cartridge and single-use capsule formats, built mainly on polyethersulfone membranes, used at harvest clarification, sterile filtration, viral clearance and final fill in biologics manufacture. Growth is supported by consumables that recur with every batch, by single-use formats that convert validation labour into recurring purchases, and by recovery from the destocking that suppressed orders through 2024. Expansion is constrained by regulatory qualification that makes installed processes practically unwinnable for challengers, by equipment demand still weakened by investment restraint, and by demand existing only where licensed manufacturing capacity exists. Competition turns on qualification and supply security rather than on price. The largest pure bioprocessing supplier grew its relevant division 9.5% in constant currencies in 2025 and guided to 5% to 9% for 2026.
Market Dynamics
Key market dynamics and their impact on the industry landscape
Market Drivers
- Consumables were identified as the main driver of divisional growth in 2025, while equipment declined on customer investment restraint. Filters are consumed per batch rather than purchased once, so demand tracks production volume and recurs for the commercial life of every licensed product.
- Single-use capsule formats replace cleaning and revalidation between batches with disposal and replacement. That shifts spending from capital equipment and validation labour into recurring consumable purchases, which is the mechanism converting manufacturing activity into filtration revenue.
- Filters in a licensed biologics process are qualified as part of the regulatory filing. Changing supplier or material requires change control and revalidation, so a specification written at approval persists for the product's commercial life and protects the incumbent's volume.
- Destocking that suppressed orders through 2024 was described by industry observers as fully behind the sector during 2025, with consumable order growth holding in double digits. Repligen product revenue rose 16.4% in 2025 after being effectively flat the previous year.
- Sartorius reported its Bioprocess Solutions division growing 9.5% in constant currencies to EUR 2.865 billion in 2025, with divisional EBITDA up 15.2% to EUR 907 million at a 31.7% margin. Margin expansion alongside volume indicates pricing held through the recovery.
Market Challenges
- The stored forecast implies 19.04% compound growth from 2024 to 2030, while the sector's largest pure bioprocessing supplier guided to 5% to 9% constant currency growth for 2026 and described conditions as normalised. The two were not reconcilable from the evidence examined.
- The 2024 base is a destocking trough rather than a normal year. Repligen product revenue was effectively flat in 2024 at USD 634,178 thousand against USD 632 million in 2023, so a high compound rate measured from that base partly reflects recovery rather than underlying expansion.
- Equipment sales declined through 2025 on industry-wide customer investment restraint, even as consumables grew. A supplier's reported growth therefore conceals two opposite trends, and filtration hardware is exposed to the weaker of them.
- Two of the five supplied Application values, Food and Beverage and Water and Wastewater Treatment, describe industrial filtration with different products, regulatory requirements and suppliers. Any figure blending them with bioprocess filtration would overstate a bioprocess-specific market.
- Qualification cuts both ways. Because filters are written into regulatory filings, an incumbent is protected but a challenger cannot win installed processes at any price, so new suppliers compete only for processes not yet validated.
Opportunities
- Cell and gene therapy manufacturing uses different consumable configurations from established biologics. Repligen's agreed acquisition of BioLife Solutions for about USD 1.5 billion indicates suppliers positioning for that shift rather than waiting for it.
- Newly licensed manufacturing capacity in Asia Pacific offers the one route to displacing incumbents, because a filter specification can be won at validation rather than fought for afterwards. Each new process is effectively a contested opening in an otherwise locked market.
- Continuous and intensified processing changes the filtration duty cycle, requiring products rated for longer run times. Suppliers with validated offerings for that mode could capture processes being designed now rather than competing for those already approved.
- Equipment demand has been suppressed by investment restraint but was described as showing increasing stabilisation. A recovery in capital spending could add a hardware cycle on top of the consumable growth already visible.
- Margin expansion during the recovery, with divisional EBITDA margin reaching 31.7%, suggests pricing power has held. Suppliers may be able to fund capacity or acquisition from operating cash rather than by raising capital.
Trends and Insights
Key market trends shaping the industry landscape
Consumables Growing, Equipment Falling
High impactShort-termConsumables were the main driver of growth in 2025 while equipment declined on customer investment restraint, though it showed increasing stabilisation.
Insight: A single headline growth rate for this market averages two opposing movements, so suppliers weighted toward disposables are performing very differently from those weighted toward hardware.
The Destocking Trough Distorts Every Comparison
High impactMid-termOne supplier's revenue was flat in 2024 and rose 16.4% in 2025, with destocking described as fully behind the sector.
Insight: Any compound rate measured from 2024 captures a recovery to trend as though it were trend growth, which is the most likely explanation for a forecast far above supplier guidance.
Regulatory Qualification Locks the Market
High impactLong-termFilters are named in the regulatory filing for a licensed process, so changing one requires change control and revalidation.
Insight: Share moves only when new processes are validated, which means the competitive contest is fought over capacity being built rather than capacity already running.
Suppliers Moving Toward New Modalities
Medium impactMid-termA filtration-led supplier agreed to acquire a cell therapy supply company for about USD 1.5 billion in 2026.
Insight: Established biologics filtration is a mature, locked business, so growth by acquisition into adjacent modalities may be a more reliable route than winning share in the core.
Demand Follows Capacity, Not Patients
Medium impactLong-termRegions without licensed biologics manufacturing generate no bioprocess filtration demand regardless of population or healthcare spending.
Insight: Regional forecasting in this market should track announced and licensed manufacturing plants rather than any healthcare demand indicator, which is unusual for a market classified under healthcare.
Segment Analysis
Market segmentation by product type, application, distribution channel, material
These five values mix filtration mechanism with housing format, which obscures the commercial division that matters. Membrane Filters and Depth Filters are mechanisms: membranes separate by defined pore size and carry sterile filtration and the tangential flow steps used for concentration and buffer exchange, while depth filters trap particles through a porous matrix and handle the cell removal step after harvest. Cartridge Filters and Capsule Filters are formats in which those membranes are supplied, with capsules pre-sterilised and disposable and cartridges installed into reusable housings. Filter Presses belong to an older mechanical filtration tradition used in chemical and food processing rather than in single-use biologics manufacture. The consumable and single-use formats are what generate recurring revenue, which matters because consumables were identified as the main driver of divisional growth in 2025 while equipment declined.
Geography Analysis
Regional market analysis
North America
North America holds the largest concentration of both suppliers and biologics manufacturing capacity. Three of the five identified suppliers are headquartered here, and the region hosts the largest installed base of licensed biologics processes, each of which locks in a qualified filter specification for the life of the product. The regional ranking rests on that documented commercial concentration rather than on a measured regional market size. No regional market size or growth figure was identified for any region in this market. The closest available evidence is one supplier's own revenue by region: Sartorius grew 8.9% in the Americas to EUR 1.251 billion in 2025. That is a single company's performance rather than a measurement of the regional market. Demand here is also tied to the recovery from destocking, which industry observers described as fully behind the sector during 2025.
Europe
Europe supplies the two largest bioprocess-focused manufacturers in this market and a substantial share of global biologics capacity. Sartorius, based in Germany, reported Bioprocess Solutions division revenue of EUR 2.865 billion for 2025, up 9.5% in constant currencies, and Merck KGaA, also German, supplies process filtration through its life science business. Sartorius recorded EMEA revenue of EUR 1.467 billion in 2025, growing 5.8%, the slowest of its three regions, though this is company revenue rather than a regional market measurement. Europe's position is therefore as the manufacturing and engineering base for the sector rather than as its fastest-expanding demand centre, and the region's suppliers set the technical standards that the regulatory filings then lock in.
Asia Pacific
Asia Pacific is the smallest of the three regions Sartorius reports and matched the highest growth rate among them, with its regional revenue rising 8.9% to EUR 820 million in 2025. Growing at the same rate from the smallest base places the region ahead on relative expansion, which is the basis for naming it fastest-growing here. That basis is a single supplier's regional revenue rather than a measured regional market, and no regional market size or growth figure was identified for this market, so the ranking is a documented judgement rather than a measurement. The structural reason to expect continued relative growth is that new biologics manufacturing capacity is being built in the region, and each new licensed process qualifies a filter specification that then persists for the product's commercial life.
Latin America
No market size, revenue or growth figure specific to Latin America was identified, and none of the suppliers examined reports the region separately. Suppliers aggregate it into an Americas figure alongside the United States and Canada, which means regional performance cannot be distinguished from the much larger North American business it is reported with. Structurally, the region has limited licensed biologics manufacturing capacity relative to its population, and bioprocess filtration demand follows manufacturing capacity rather than patient numbers, because the filters are consumed during production rather than at the point of care. Where capacity is absent, the region imports finished biologics and generates no bioprocess filtration demand at all.
Middle East & Africa
No market size, revenue or growth figure specific to the Middle East and Africa was identified, and suppliers report it within an EMEA aggregate that is dominated by Europe. The determining factor is the same as in Latin America: bioprocess filtration is consumed during biologics manufacture, so demand exists only where licensed manufacturing capacity exists. Several countries in the region have announced biomanufacturing initiatives, but a filtration market follows a licensed process rather than an announcement, because the specification is fixed at validation and revenue begins at commercial production. Until capacity is licensed and running, the region remains a destination for finished product rather than a source of process consumable demand.
Competitive Landscape
Key players and market positioning analysis
Competition in bioprocess filtration is shaped less by product differentiation than by regulatory qualification, because a filter named in a licensed biologics filing cannot be changed without change control and revalidation. Incumbency on an approved process is therefore close to durable, and share moves mainly when new processes are validated. Sartorius AG is the largest pure-play participant, reporting Bioprocess Solutions division revenue of EUR 2.865 billion for 2025, growth of 9.5% in constant currencies, and divisional EBITDA of EUR 907 million at a 31.7% margin, within group revenue of EUR 3.538 billion. Its regional revenue was EUR 1.467 billion in EMEA, EUR 1.251 billion in the Americas and EUR 820 million in Asia Pacific. Danaher Corporation competes through Pall and Cytiva, giving it filtration alongside chromatography and single-use systems, and it signalled recovering bioprocessing demand as customers increased spending after a period of destocking. Merck KGaA supplies process filtration through its life science business, drawing on the Millipore franchise. Repligen Corporation is the most filtration-weighted of the group, with filtration products of USD 402.8 million within total 2025 product revenue of USD 737,960 thousand, up 16.4%, and it agreed to acquire BioLife Solutions for about USD 1.5 billion to extend into cell therapy. Thermo Fisher Scientific Inc. reaches the same customers through a broader bioproduction portfolio. The principal competitive factors are qualification on existing processes, validated performance for the specific unit operation, security of supply for a consumable that stops production if unavailable, and increasingly the ability to serve new modalities where no specification has yet been fixed.
Major Players
Leading companies in the market
Industry Developments
6 recorded developments
Repligen agreed to acquire BioLife Solutions in a cash-and-stock transaction valued at about USD 1.5 billion, extending into cell therapy. A filtration-led supplier moved toward a modality with different consumable requirements from established biologics manufacturing.
Sartorius guided to 5% to 9% constant currency sales growth for 2026 with underlying EBITDA margin slightly above 30%, describing market conditions as normalised. The sector's largest pure bioprocessing supplier set expectations well below the rate implied by the stored forecast for this market.
Repligen reported 2025 product revenue of USD 737,960 thousand, up 16.4%, with filtration products contributing USD 402.8 million. Filtration is the largest of its four product lines, ahead of chromatography at USD 153.2 million, proteins at USD 97.4 million and process analytics at USD 81.2 million.
Sartorius reported group sales revenue of EUR 3.538 billion for 2025, up 7.6% in constant currencies, with its Bioprocess Solutions division growing 9.5% in constant currencies to EUR 2.865 billion. Divisional EBITDA rose 15.2% to EUR 907 million at a 31.7% margin.
Danaher signalled a recovery in bioprocessing demand as biotechnology and pharmaceutical customers increased spending, with industry observers describing destocking as fully behind the sector and consumable order growth holding in double digits.
Repligen reported 2024 product revenue of USD 634,178 thousand against USD 632 million in 2023, effectively flat, as customers worked down inventory built during the pandemic. The fourth quarter rose 13% year on year, which was the first clear sign that destocking was ending.
Table of Contents
13 comprehensive chapters
1.1 Market Definition
1.2 Scope of the Study
1.3 Research Objectives
2.1 Research Approach
2.2 Data Sources
2.3 Market Estimation Approach
2.4 Forecast Assumptions
2.5 Research Limitations
3.1 Market Overview
3.2 Market Size and Forecast
3.3 Key Findings
3.4 Market Structure
4.1 Market Drivers
4.2 Market Challenges
4.3 Market Opportunities
4.4 Market Trends and Insights
5.1 Market Segmentation Overview
5.2 By Product Type
5.3 By Application
5.4 By Distribution Channel
5.5 By Material
6.1 North America
6.2 Europe
6.3 Asia Pacific
6.4 Latin America
6.5 Middle East & Africa
6.6 Regional Market Comparison
7.1 Industry Developments
7.2 Industry Timeline
8.1 Market Structure and Competitive Positioning
8.2 Major Players
8.3 Strategic Developments
8.4 Key Competitive Factors
9.1 Sartorius AG
9.2 Danaher Corporation
9.3 Merck KGaA
9.4 Repligen Corporation
9.5 Thermo Fisher Scientific Inc.
10.1 Market Size and Growth Outlook
10.2 Regional Market Outlook
10.3 Future Market Trends
10.4 Key Risks to the Forecast
11.1 Growth Opportunities
11.2 Key Risks and Constraints
11.3 Strategic Considerations
13.1 Glossary of Terms
13.2 Abbreviations
13.3 Research References
Scope of the Report
Report coverage and methodology
Study Period
Base Year: 2024
Forecast Period: 2024 - 2030
Geographic Scope
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Covered
Sartorius AG, Danaher Corporation, Merck KGaA, Repligen Corporation + more
Data Sources
Primary research, industry interviews, regulatory filings, company reports
Frequently Asked Questions
Common questions about this report
Ready to Get the Full Report?
Access comprehensive market insights, detailed analysis, and strategic recommendations to make informed business decisions.